MedTrace Logo

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

NCT04276376 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2025-12-01

No results posted yet for this study

Summary

The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate

Conditions

Interventions

DRUG

Atezolizumab

Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w

DRUG

Rucaparib

Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-12
Primary Completion
2023-01-25
Completion
2023-12-12

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04276376 on ClinicalTrials.gov